Phost’in develops First-in-Class N-glycosylation inhibitors for the treatment of cancers and fibrosis (First-in-Human currently on-going in Europe for the first program).

PhOx430, First-In-Class selective GnT-V inhibitor, now evaluated in Ph.I in patients with Advance Solid Tumors.

–  Therapeutic areas: Oncology, Fibrosis

–  Based in: Montpellier (FRANCE)

–  Employees: 1-10

–  Created in: 2014